Filing Details

Accession Number:
0001209191-15-036748
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-04-28 18:09:47
Reporting Period:
2015-04-24
Filing Date:
2015-04-28
Accepted Time:
2015-04-28 18:09:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1509190 Aratana Therapeutics Inc. PETX Pharmaceutical Preparations (2834) 383826477
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1336284 Linda Rhodes C/O Aratana Therapeutics, Inc.
1901 Olathe Boulevard
Kansas City KS 66103
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-04-24 17,200 $0.00 438,205 No 4 A Direct
Common Stock Disposition 2015-04-27 11,700 $14.78 426,505 No 4 S Direct
Common Stock Disposition 2015-04-27 3,300 $15.78 423,205 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2014.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.47 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2014. This sale constitutes the final sale under such trading plan.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.52 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.